Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5076)
All Articles published online
|
Publishing Process of This Article
|
Jul 24, 2019 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Passler M, Taube ET, Sehouli J, Pietzner K. Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report. World J Clin Oncol 2019; 10(7): 247-255 [PMID: 31396474 DOI: 10.5306/wjco.v10.i7.247] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v10/i7/247.htm |
| Number | Citing Articles |
| 1 |
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S Ohashi, David G Brooks, Gini F Fleming. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. Journal for ImmunoTherapy of Cancer 2022; 10(3): e004233 doi: 10.1136/jitc-2021-004233
|
| 2 |
Anna Pawłowska, Wiktoria Skiba, Dorota Suszczyk, Weronika Kuryło, Joanna Jakubowicz-Gil, Roman Paduch, Iwona Wertel. The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients. Cancers 2022; 14(23): 5757 doi: 10.3390/cancers14235757
|
| 3 |
Alessia Cimadamore, Liang Cheng, Marina Scarpelli, Antonio Lopez-Beltran, Veronica Mollica, Rodolfo Montironi, Francesco Massari. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. European Urology 2021; 79(1): e17 doi: 10.1016/j.eururo.2020.09.047
|
| 4 |
Anna Pawłowska, Anna Rekowska, Weronika Kuryło, Anna Pańczyszyn, Jan Kotarski, Iwona Wertel. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 2023; 24(13): 10859 doi: 10.3390/ijms241310859
|